AcSDKP plasma concentrations in patients with solid tumours: comparison of two chemotherapeutic regimens

This publication has 8 references indexed in Scilit:

• Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
  Journal of Clinical Investigation, 1996
• AcSDKP serum concentrations vary during chemotherapy in patients with acute myeloid leukaemia
  British Journal of Haematology, 1995
• The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism
  Blood, 1994
• Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline
  Biochemical Journal, 1993
• Direct and reversible inhibitory effect of the tetrapeptide acetyl-N- Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors
  Blood, 1993
• Distribution of a negative regulator of haematopoietic stem cell proliferation (AcSDKP) and thymosin, β4 in mouse tissues
  FEBS Letters, 1991
• Amelioration of Chemotherapy‐Induced Toxicity by Cotreatment with AcSDKP, a Tetrapeptide Inhibitor of Hematopoietic Stem Cell Proliferation
  Annals of the New York Academy of Sciences, 1991
• Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay
  Biochemical and Biophysical Research Communications, 1990